FDA's Lead Reviewer for DONED to Give Talk at 2nd Annual TBI Conference

Printer-friendly versionPDF version

FDA's Lead Reviewer for DONED to Give Regulatory Perspective on Development & Validation of Diagnostic Devices for Traumatic Brain Injury at 2nd Annual TBI Conference

Minneapolis, MN, United States., February 9, 2012 - (PressReleasePoint) - The development of valid diagnostic devices for traumatic brain injury (TBI) poses numerous challenges with respect to proper study design, subject selection (e.g., severity of TBI), and clinical assessment. Currently, no single TBI diagnostic “gold standard” exists making validation of novel diagnostic devices for TBI problematic. Currently, there are no approved TBI diagnostic devices. Dr. Peter Como will address some of the key issues in the validation of TBI diagnostic devices from a regulatory perspective, including the essential elements required for FDA approval of a TBI diagnostic device. 
 
The world's leading experts in the field of traumatic brain injury are meeting in Washington, DC on March 6-7 for the the 2nd Annual Traumatic Brain Injury Conference. This conference will address current opportunities and challenges in traumatic brain injury, from a diagnostic and therapeutic perspective. Individuals involved in the following areas will be presenting as well as attending: biomarkers, assay development, drug discovery, regulatory, imaging, diagnostics.
 
Please visit www.tbiconference.com for the full list of speakers and information on how to register to attend.

Arrowhead Conferences utilize our expertise as a leading publisher of healthcare market reports to provide delegates with well-rounded conferences which highlight industry trends, provide case studies and analyze the state of the biotech and pharmaceutical industries.
 

Arrowhead Conferences are organized to heighten person-to-person communications via networking sessions and social events, as well as panel discussions which raise the level of conversation and encourage audience participation.